Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 13:00:29 UTC |
---|
Update Date | 2021-09-26 23:07:41 UTC |
---|
HMDB ID | HMDB0254011 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Lenvatinib |
---|
Description | Lenvatinib, also known as e 7080 or unii-ee083865g2, belongs to the class of organic compounds known as quinoline carboxamides. These are quinolines in which the quinoline ring system is substituted by one or more carboxamide groups. Lenvatinib is a very strong basic compound (based on its pKa). The substance is almost completely (98–99%) bound to plasma proteins, mainly albumin. In August 2018, the FDA lenvatinib for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Lenvatinib is approved (since 2015) for the treatment of differentiated thyroid cancer that is either locally recurrent or metastatic, progressive, and did not respond to treatment with radioactive iodine (radioiodine). Lenvatinib is absorbed quickly from the gut, reaching peak blood plasma concentrations after one to four hours (three to seven hours if taken with food). This compound has been identified in human blood as reported by (PMID: 31557052 ). Lenvatinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Lenvatinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28) |
---|
Synonyms | Value | Source |
---|
4-(3-Chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide | ChEBI | e 7080 | ChEBI | e7080 | ChEBI | UNII-ee083865g2 | ChEBI | 4-(3-chloro-4-((Cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide | MeSH | Lenvima | MeSH |
|
---|
Chemical Formula | C21H19ClN4O4 |
---|
Average Molecular Weight | 426.86 |
---|
Monoisotopic Molecular Weight | 426.1094828 |
---|
IUPAC Name | 4-{3-chloro-4-[(cyclopropyl-C-hydroxycarbonimidoyl)amino]phenoxy}-7-methoxyquinoline-6-carboximidic acid |
---|
Traditional Name | 4-{3-chloro-4-[(cyclopropyl-C-hydroxycarbonimidoyl)amino]phenoxy}-7-methoxyquinoline-6-carboximidic acid |
---|
CAS Registry Number | Not Available |
---|
SMILES | COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N |
---|
InChI Identifier | InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28) |
---|
InChI Key | WOSKHXYHFSIKNG-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as quinoline carboxamides. These are quinolines in which the quinoline ring system is substituted by one or more carboxamide groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Quinolines and derivatives |
---|
Sub Class | Quinoline carboxamides |
---|
Direct Parent | Quinoline carboxamides |
---|
Alternative Parents | |
---|
Substituents | - Quinoline-6-carboxamide
- Diaryl ether
- N-phenylurea
- Phenoxy compound
- Anisole
- Phenol ether
- Alkyl aryl ether
- Halobenzene
- Chlorobenzene
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- Pyridine
- Benzenoid
- Heteroaromatic compound
- Carboxamide group
- Primary carboxylic acid amide
- Carbonic acid derivative
- Urea
- Azacycle
- Carboxylic acid derivative
- Ether
- Organonitrogen compound
- Organooxygen compound
- Organic oxygen compound
- Organic nitrogen compound
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organochloride
- Organohalogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Lenvatinib,3TMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N)O[Si](C)(C)C | 3669.2 | Semi standard non polar | 33892256 | Lenvatinib,3TMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N)O[Si](C)(C)C | 3196.9 | Standard non polar | 33892256 | Lenvatinib,3TMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N)O[Si](C)(C)C | 4933.5 | Standard polar | 33892256 | Lenvatinib,3TMS,isomer #2 | COC1=CC2=NC=CC(OC3=CC=C(NC(=NC4CC4)O[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C)O[Si](C)(C)C | 3762.6 | Semi standard non polar | 33892256 | Lenvatinib,3TMS,isomer #2 | COC1=CC2=NC=CC(OC3=CC=C(NC(=NC4CC4)O[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C)O[Si](C)(C)C | 3216.0 | Standard non polar | 33892256 | Lenvatinib,3TMS,isomer #2 | COC1=CC2=NC=CC(OC3=CC=C(NC(=NC4CC4)O[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C)O[Si](C)(C)C | 5160.6 | Standard polar | 33892256 | Lenvatinib,3TMS,isomer #3 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(O)=N[Si](C)(C)C | 3591.7 | Semi standard non polar | 33892256 | Lenvatinib,3TMS,isomer #3 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(O)=N[Si](C)(C)C | 3259.2 | Standard non polar | 33892256 | Lenvatinib,3TMS,isomer #3 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(O)=N[Si](C)(C)C | 4929.0 | Standard polar | 33892256 | Lenvatinib,3TMS,isomer #4 | COC1=CC2=NC=CC(OC3=CC=C(N(C(O)=NC4CC4)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C)O[Si](C)(C)C | 3642.5 | Semi standard non polar | 33892256 | Lenvatinib,3TMS,isomer #4 | COC1=CC2=NC=CC(OC3=CC=C(N(C(O)=NC4CC4)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C)O[Si](C)(C)C | 3293.0 | Standard non polar | 33892256 | Lenvatinib,3TMS,isomer #4 | COC1=CC2=NC=CC(OC3=CC=C(N(C(O)=NC4CC4)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C)O[Si](C)(C)C | 4950.0 | Standard polar | 33892256 | Lenvatinib,4TMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C)O[Si](C)(C)C | 3575.4 | Semi standard non polar | 33892256 | Lenvatinib,4TMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C)O[Si](C)(C)C | 3122.5 | Standard non polar | 33892256 | Lenvatinib,4TMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C)[Si](C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C)O[Si](C)(C)C | 4535.6 | Standard polar | 33892256 | Lenvatinib,3TBDMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N)O[Si](C)(C)C(C)(C)C | 4280.1 | Semi standard non polar | 33892256 | Lenvatinib,3TBDMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N)O[Si](C)(C)C(C)(C)C | 3697.8 | Standard non polar | 33892256 | Lenvatinib,3TBDMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N)O[Si](C)(C)C(C)(C)C | 4849.3 | Standard polar | 33892256 | Lenvatinib,3TBDMS,isomer #2 | COC1=CC2=NC=CC(OC3=CC=C(NC(=NC4CC4)O[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4335.0 | Semi standard non polar | 33892256 | Lenvatinib,3TBDMS,isomer #2 | COC1=CC2=NC=CC(OC3=CC=C(NC(=NC4CC4)O[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3677.6 | Standard non polar | 33892256 | Lenvatinib,3TBDMS,isomer #2 | COC1=CC2=NC=CC(OC3=CC=C(NC(=NC4CC4)O[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 5032.8 | Standard polar | 33892256 | Lenvatinib,3TBDMS,isomer #3 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(O)=N[Si](C)(C)C(C)(C)C | 4210.5 | Semi standard non polar | 33892256 | Lenvatinib,3TBDMS,isomer #3 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(O)=N[Si](C)(C)C(C)(C)C | 3755.0 | Standard non polar | 33892256 | Lenvatinib,3TBDMS,isomer #3 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(O)=N[Si](C)(C)C(C)(C)C | 4892.8 | Standard polar | 33892256 | Lenvatinib,3TBDMS,isomer #4 | COC1=CC2=NC=CC(OC3=CC=C(N(C(O)=NC4CC4)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4286.8 | Semi standard non polar | 33892256 | Lenvatinib,3TBDMS,isomer #4 | COC1=CC2=NC=CC(OC3=CC=C(N(C(O)=NC4CC4)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3809.2 | Standard non polar | 33892256 | Lenvatinib,3TBDMS,isomer #4 | COC1=CC2=NC=CC(OC3=CC=C(N(C(O)=NC4CC4)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4934.9 | Standard polar | 33892256 | Lenvatinib,4TBDMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4288.6 | Semi standard non polar | 33892256 | Lenvatinib,4TBDMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3739.4 | Standard non polar | 33892256 | Lenvatinib,4TBDMS,isomer #1 | COC1=CC2=NC=CC(OC3=CC=C(N(C(=NC4CC4)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(Cl)=C3)=C2C=C1C(=N[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4615.6 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-5869200000-75491f68cd3120aa8532 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TMS_1_4) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TBDMS_1_4) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TBDMS_2_2) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TBDMS_2_3) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TBDMS_2_4) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TBDMS_2_5) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenvatinib GC-MS (TBDMS_2_6) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 10V, Positive-QTOF | splash10-056r-6003900000-04cb6f15c2a0a0f71843 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 20V, Positive-QTOF | splash10-0a4i-9015300000-e10b9619aa1a1b37cd46 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 40V, Positive-QTOF | splash10-0a4r-9001000000-96f3b3d2ef3192e9dbd4 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 10V, Negative-QTOF | splash10-056u-7009700000-e3f3c5860d7691f9857d | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 20V, Negative-QTOF | splash10-052f-8019200000-3d0288e1da4b9e37dc46 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 40V, Negative-QTOF | splash10-052f-9212000000-b47fa72109a9da8633f4 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 10V, Positive-QTOF | splash10-004i-0001900000-16289db81484777d708c | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 20V, Positive-QTOF | splash10-0a4i-9001100000-bfb4b6470a19c9710605 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 40V, Positive-QTOF | splash10-0a6r-5129200000-dc7c18864a3c85c7403b | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 10V, Negative-QTOF | splash10-0g29-4009500000-394985c4da8780f25064 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 20V, Negative-QTOF | splash10-0006-9117200000-38e8e55ae37e20d85ccf | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenvatinib 40V, Negative-QTOF | splash10-001i-9001100000-9322f1b2183c87325b7b | 2021-10-12 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | Not Available |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected but not Quantified | Not Quantified | Not Specified | Not Specified | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB09078 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | Not Available |
---|
KEGG Compound ID | Not Available |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Lenvatinib |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 9823820 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 85994 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Barupal DK, Fiehn O: Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach. Environ Health Perspect. 2019 Sep;127(9):97008. doi: 10.1289/EHP4713. Epub 2019 Sep 26. [PubMed:31557052 ]
|
---|